New combo therapy tested to slow down type 1 diabetes

NCT ID NCT06338553

Recruiting now Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a GLP-1 drug (semaglutide) to an existing immunotherapy (teplizumab) can better manage early Type 1 diabetes. Researchers want to see if this combination helps control blood sugar after meals, improves how the body uses insulin, and supports blood vessel health. The study involves 24 participants who will undergo meal tests and receive either the GLP-1 drug or a placebo to compare effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TYPE 1 DIABETES